Stop Chasing Groupon!

A recent article from Fortune discusses the exodus of VC funding from the life sciences space.  With all of the uncertainty taking place with healthcare reform, many VCs are shifting capital to IT.  The recent (and coming) high profile IPOs (See LinkedIn, Groupon, etc.) have many investors trying to jump on the bandwagon far too late in the game.  Hopefully this shift is only temporary and doesn't lead to a lack of capital for the next generation of  life sciences start ups.